Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05984017 | A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma | unknown | — | 130 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06187740 | Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | unknown | Phase 1 | 28 | Fudan UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02037048 |
| FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma |
| unknown |
| Phase 2 |
| 63 |
| Case Comprehensive Cancer CenterOTHER |
| 1 |
| Jan 8, 2024 |
| clinicaltrials |
| NCT05185531 | A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma(Notable-HCC) | unknown | Phase 1 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06190847 | Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer | unknown | — | 97 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06192030 | Machine Learning Predicts Survival and Mutations in Ovarian Metastases of Colorectal Cancer | unknown | — | 200 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05626569 | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06178809 | Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma | unknown | — | 475 | Singlera Genomics Inc.INDUSTRY | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06144385 | A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 20 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06171854 | caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.(ABACO) | unknown | Phase 2 | 33 | University of Campania Luigi VanvitelliOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06186609 | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC | unknown | Phase 2 | 68 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT06125262 | Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC. | unknown | — | 100 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT04266327 | RISI in the Treatment of Recurrent Metastatic SCC of Thoracic Inlet Lymph Nodes | unknown | N/A | 30 | Peking University Third HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04401059 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study(SELECT-2) | unknown | Phase 4 | 744 | Tian XieOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05991180 | Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | — | 160 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06182735 | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma | unknown | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06182865 | A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy | unknown | N/A | 10 | National Atomic Research Institute, TaiwanOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04422249 | A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy | unknown | N/A | 95 | Southwest Hospital, ChinaOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06170697 | Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 46 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05031949 | Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma(CCGLC-003) | unknown | Phase 1 | 20 | Zhang Bi Xiang, MDOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05103007 | PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer(CCGLC-004) | unknown | N/A | 200 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05520801 | Primary Hepatobiliary Cancer Cohort of Central China(CCGLC-002) | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05533892 | Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC(CCGLC-007) | unknown | Phase 1 | 30 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05839197 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC(CCGLC-010) | unknown | Phase 2 | 38 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT03812393 | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast(FACT-2) | unknown | Phase 2 | 27 | West Cancer CenterOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04197687 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | unknown | Phase 2 | 480 | Academic and Community Cancer Research UnitedOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04559607 | TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma | unknown | N/A | 188 | Zhongda HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05070156 | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma | unknown | Early Phase 1 | 3 | Tongji UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | unknown | Phase 3 | 194 | Hutchison Medipharma LimitedINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06163365 | Inherited Cancer Early Diagnosis (ICED) Study(ICED) | unknown | — | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT03108703 | Assessment of QoL and Outcomes With SBRT for RCC(AQuOS-RCC) | unknown | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT03839706 | Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation(PETMRIinHCC) | unknown | N/A | 20 | University Health Network, TorontoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04450732 | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | unknown | Phase 1 | 96 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 5, 2023 | clinicaltrials |
| NCT04985851 | To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. | unknown | N/A | 90 | Shanghai Chest HospitalOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06152783 | Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study | unknown | — | 578 | Changhai HospitalOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06154109 | Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial | unknown | Phase 2 | 90 | Zhiyu WangOTHER | 0 | Dec 1, 2023 | clinicaltrials |
| NCT06151691 | Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach | unknown | — | 51 | Fudan UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05429190 | Validation of SMS Protocol for HCC Screening in High-risk Patients | unknown | — | 470 | Erasmus Medical CenterOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05964621 | Venous Thromboembolism in Primary Pancreatic Tumour Resection(PaTR-VTE) | unknown | — | 64 | University of ThessalyOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02937155 | In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer? | unknown | — | 100 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05709171 | Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms | unknown | Phase 2 | 200 | Rigshospitalet, DenmarkOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06107114 | Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma(CZCNRHNSCC) | unknown | Phase 2 | 52 | Xuekui LiuOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06134973 | A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. | unknown | — | 1,000 | Tianjin Third Central HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06142318 | Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 66 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04040530 | Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours | unknown | — | 187 | Region of Southern DenmarkOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04253145 | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 184 | Fundacion OncosurNETWORK | 1 | Nov 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 10, 2024source: clinicaltrials